Background
Methods
Ethical approval
Study population
Data collection and definition of variables
Microbiological cultures
Statistical analyses
Sensitivity and subgroup analyses
Results
Characteristics of the enrolled subjects with critical illness
All | Non-survivors | Survivors | p value | |
---|---|---|---|---|
(N = 4488) | (N = 2477) | (N = 2011) | ||
Basic characteristics | ||||
Age, years | 66.4 ± 16.4 | 69.7 ± 15.5 | 62.3 ± 16.6 | < 0.01 |
Sex (male) | 2866 (63.9%) | 1634 (66.0%) | 1232(61.3%) | < 0.01 |
Body mass index | 24.4 ± 4.7 | 23.9 ± 4.7 | 24.9 ± 4.7 | < 0.01 |
Charlson comorbidity index | 2.4 ± 1.6 | 2.7 ± 1.6 | 2.0 ± 1.5 | < 0.01 |
Immunocompromised patients | 953 (21.2%) | 578 (23.3%) | 375(18.7%) | < 0.01 |
Malignancy, active | 601 (13.4%) | 508 (20.5%) | 93 (4.6%) | < 0.01 |
Solid tumor, active | 427 (9.5%) | 372 (15.0%) | 55 (2.7%) | < 0.01 |
Hematological malignancy | 174 (3.9%) | 136 (5.5%) | 38 (1.9%) | < 0.01 |
Autoimmune diseases | 107 (2.4%) | 54 (2.2%) | 53 (2.6%) | 0.32 |
Organ transplant recipients | 15 (0.3%) | 7 (0.3%) | 8 (0.4%) | 0.51 |
Follow-up duration, years | 1.2 ± 1.3 | 0.4 ± 0.8 | 2.2 ± 1.3 | < 0.01 |
Etiology for ICU admission | ||||
Sepsis with acute respiratory failure | 2584 (57.6%) | 1668 (67.3%) | 916 (45.5%) | < 0.01 |
Acute neurological conditions | 431 (10.6%) | 170 (7.0%) | 261 (13.0%) | |
Acute cardiac conditions | 190 (4.2%) | 42 (1.7%) | 148 (7.4%) | |
Acute gastrointestinal condition | 174 (3.9%) | 109 (4.4%) | 65 (3.2%) | |
Acute renal conditions | 121 (2.7%) | 56 (2.3%) | 65 (3.2%) | |
Major surgery | 101 (2.3%) | 35 (1.4%) | 66 (3.3%) | |
Cardiac arrest | 25 (0.6%) | 22 (0.9%) | 3 (0.2%) | |
Others | 862 (19.2%) | 375 (15.1%) | 487 (24.2%) | |
Severity and managements | ||||
APACHE II score | 25.1 ± 7.5 | 27.7 ± 7.0 | 21.9 ± 6.7 | < 0.01 |
Presence of shock | 2068 (46.1%) | 1476 (59.6%) | 592 (29.4%) | < 0.01 |
Receiving mechanical ventilation | 3295 (73.4%) | 2044 (82.5%) | 1,251 (62.2%) | < 0.01 |
Renal replacement therapy (RRT) | ||||
Temporal RRT during admission | 708 (15.8%) | 533 (21.5%) | 175 (8.7%) | < 0.01 |
RRT for ESRD | 125 (2.8%) | 68 (2.8%) | 57 (2.8%) | 0.86 |
Fluid balance, day 1–3, mL | 717.6 ± 3727.4 | 1408.7 ± 4106.1 | − 133.6 ± 2988.9 | < 0.01 |
Microbiologic data | ||||
Positive culture, any culture site | 2362 (52.6%) | 1608 (64.9%) | 754 (37.5%) | < 0.01 |
Blood | 631 (14.1%) | 491 (19.8%) | 140 (7.0%) | < 0.01 |
Respiratory Tract | 1823 (40.6%) | 1267(51.2%) | 556 (27.7%) | < 0.01 |
Urinary Tract | 831 (18.5%) | 607 (24.5%) | 224 (11.1%) | < 0.01 |
Other sites | 160 (3.6%) | 111 (4.5%) | 49 (2.4%) | < 0.01 |
Positive MDRO1 | 1286 (28.7%) | 925 (37.3%) | 361 (18.0%) | < 0.01 |
Outcomes | ||||
ICU-stay, days | 9.9 ± 8.4 | 11.3 ± 8.8 | 8.3 ± 7.6 | < 0.01 |
Hospital-stay, days | 24.2 ± 19.1 | 26.4 ± 19.7 | 21.6 ± 17.8 | < 0.01 |
Ventilator-day | 9.8 ± 9.1 | 10.8 ± 9.6 | 8.1 ± 8.0 | < 0.01 |
Mortality at distinct time points | ||||
In-hospital mortality | 1260 (28.1%) | 1260 (50.9%) | NA | NA |
90-day mortality | 1707 (38.0%) | 1707 (68.9%) | NA | NA |
1-year mortality | 2117 (47.2%) | 2117 (85.5%) | NA | NA |
Main pathogens in distinct culture sites among critically ill patients
Total | Blood | Respiratory tract | Urinary tract | Others | ||||||
---|---|---|---|---|---|---|---|---|---|---|
(N = 2362) | (N = 593) | (N = 1831) | (N = 831) | (N = 352) | ||||||
n | % | n | % | n | % | n | % | n | % | |
Gram-positive cocci | N = 584 | N = 211 | N = 246 | N = 143 | N = 89 | |||||
Staphylococcus aureus | 292 | 50.0% | 92 | 43.6% | 219 | 89.0% | 6 | 4.2% | 30 | 33.7% |
Enterococcus faecium | 131 | 22.4% | 39 | 18.5% | 2 | 0.8% | 78 | 54.5% | 26 | 29.2% |
Enterococcus faecalis | 55 | 9.4% | 8 | 3.8% | 0 | 0.0% | 38 | 26.6% | 13 | 14.6% |
Gram-negative bacilli | N = 1720 | N = 389 | N = 1379 | N = 383 | N = 215 | |||||
Pseudomonas aeruginosa | 513 | 29.8% | 42 | 10.8% | 446 | 32.3% | 65 | 17.0% | 33 | 15.3% |
Klebsiella pneumoniae | 562 | 32.7% | 126 | 32.4% | 415 | 30.1% | 95 | 24.8% | 51 | 23.7% |
Acinetobacter baumannii | 402 | 23.4% | 41 | 10.5% | 357 | 25.9% | 33 | 8.6% | 27 | 12.6% |
Escherichia coli | 342 | 19.9% | 96 | 24.7% | 104 | 7.5% | 151 | 39.4% | 51 | 23.7% |
Enterobacter cloacae | 85 | 4.9% | 19 | 4.9% | 53 | 3.8% | 9 | 2.3% | 16 | 7.4% |
Serratia marcescens | 52 | 3.0% | 9 | 2.3% | 41 | 3.0% | 2 | 0.5% | 3 | 1.4% |
Proteus mirabilis | 40 | 2.3% | 8 | 2.1% | 16 | 1.2% | 12 | 3.1% | 11 | 5.1% |
Enterobacter aerogenes | 34 | 2.0% | 4 | 1.0% | 24 | 1.7% | 7 | 1.8% | 6 | 2.8% |
Haemophilus influenzae | 31 | 1.8% | 0 | 0.0% | 31 | 2.2% | 0 | 0.0% | 0 | 0.0% |
Candida/Yeast | N = 632 | N = 64 | N = 264 | N = 367 | N = 38 | |||||
Candida albicans | 436 | 69.0% | 36 | 5.7% | 200 | 31.6% | 231 | 36.6% | 31 | 4.9% |
Candida glabrata | 126 | 19.9% | 15 | 2.4% | 27 | 4.3% | 81 | 12.8% | 10 | 1.6% |
Candida tropicalis | 77 | 12.2% | 11 | 1.7% | 35 | 5.5% | 35 | 5.5% | 6 | 0.9% |
Candida parapsilosis | 12 | 1.9% | 0 | 0.0% | 7 | 1.1% | 5 | 0.8% | 0 | 0.0% |
Candida krusei | 2 | 0.3% | 0 | 0.0% | 2 | 0.3% | 0 | 0% | 0 | 0.0% |
Yeast | 45 | 7.1% | 45 | 7.1% | 1 | 0.2% | 44 | 7% | 0 | 0.0% |
Aspergillus | N = 108 | N = 0 | N = 107 | N = 0 | N = 1 | |||||
Aspergillus fumigatus | 58 | 53.7% | 0 | 0.0% | 58 | 54.2% | 0 | 0.0% | 0 | 0.0% |
Aspergillus flavus | 31 | 28.7% | 0 | 0.0% | 30 | 28.0% | 0 | 0.0% | 1 | 100% |
Aspergillus niger | 10 | 9.3% | 0 | 0.0% | 10 | 9.3% | 0 | 0.0% | 0 | 0.0% |
Aspergillus terreus | 9 | 8.3% | 0 | 0.0% | 9 | 8.4% | 0 | 0.0% | 0 | 0.0% |
Association between microbial culture and long-term mortality
Characteristics | Univariable Univariable | Multivariable | ||
---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | |
Age, per 1 year increment | 1.017 (1.014–1.019) | < 0.001 | 1.008 (1.005–1.010) | < 0.001 |
Male gender | 1.136 (1.046–1.235) | 0.003 | 1.201 (1.104–1.308) | < 0.001 |
Body mass index, per 1 decrement | 1.025 (1.016–1.034) | < 0.001 | 1.035 (1.026–1.045) | < 0.001 |
Charlson comorbidity index, per 1 increment | 1.192 (1.166–1.219) | < 0.001 | 1.120 (1.093–1.148) | < 0.001 |
APACHE II, per 1 increment | 1.095 (1.089–1.102) | < 0.001 | 1.053 (1.046–1.061) | < 0.001 |
Receiving mechanical ventilation | 2.093 (1.887–2.322) | < 0.001 | 1.068 (0.953–1.198) | 0.256 |
Fluid overload, day 1–3, per 1 L increment | 1.096 (1.085–1.106) | < 0.001 | 1.050 (1.039–1.061) | < 0.001 |
Receiving renal replacement therapy | 2.309 (2.097–2.543) | < 0.001 | 1.469 (1.324–1.631) | < 0.001 |
Presence of shock | 2.565 (2.366–2.780) | < 0.001 | 1.521 (1.387–1.667) | < 0.001 |
Immunocompromised patients | 2.418 (2.200–2.658) | < 0.001 | 2.341 (2.123–2.581) | < 0.001 |
Positive culture of MDRO1 | 1.774 (1.635–1.925) | < 0.001 | 1.008 (1.005–1.010`) | < 0.001 |
Culture site | ||||
Blood | 2.141 (1.938–2.364) | < 0.001 | 1.233 (1.104–1.378) | < 0.001 |
Respiratory tract | 1.873 (1.731–2.028) | < 0.001 | 1.217 (1.109–1.337) | < 0.001 |
Urinary tract | 1.648 (1.504–1.807) | < 0.001 | 1.230 (1.109–1.364) | < 0.001 |
Skin and soft tissue | 1.519 (1.198–1.927) | 0.001 | 0.943 (0.741–1.200) | 0.633 |
Abdomen | 1.835 (1.516–2.223) | < 0.001 | 1.028 (0.846–1.249) | 0.780 |
Distinct definitions of culture positivity | Adjusted HR* (95% CI) |
---|---|
Pathogens | |
At least one pathogen (main finding) | 1.27 (1.15–1.42) |
At least two pathogens | 1.40 (1.24–1.58) |
At least three pathogens | 1.52 (1.35–1.71) |
Culture sites | |
At least one site (main finding) | 1.29 (1.17–1.42) |
At least two sites | 1.44 (1.28–1.62) |
At least three sites | 1.67 (1.44–1.94) |